Celixir
Sabena Sultan has extensive experience in research and academia. Sabena started their career as a Postdoctoral Scientist at Rayne Institute, UCL from February 2002 to February 2005. Sabena then moved to King's College London, where they worked as a Principal Grant Investigator from 2007 to 2011. Currently, they are the Global Head of Research at Celixir since April 2011.
Sabena Sultan obtained a Doctor of Philosophy (PhD) degree in Cardiovascular Science from Imperial College London. Sabena completed their studies at the university from 1998 to 2001.
This person is not in any teams
Celixir
Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.